Compare Crispr Therapeutics AG (CRSP) vs Harley-Davidson Inc (HOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Harley-Davidson Inc — how do they compare? Crispr Therapeutics AG trades at $50.61 (market cap $4.97B), while Harley-Davidson Inc trades at $25.23 (market cap $2.64B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and Harley-Davidson Inc pays a 2.93% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | HOG | |
|---|---|---|
Market Cap | $4.97B | $2.64B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $31.03 |
52-Week Low | $44.34 | $17.19 |
Enterprise Value | $3.32B | $3.04B |
Dividend Yield | — | 2.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Harley-Davidson (HOG) trades at $25.39, up 0.99% with a bullish technical signal from moving averages. The stock shows mixed fundamentals with declining revenue from $5.8B in 2022 to $4.5B in 2025 and net income dropping to $339M, though valuation ratios remain attractive with P/E of 13.16 and P/B of 0.87. Recent news highlights production returning to US facilities and Q2 2026 earnings scheduled for July 23, 2026.
The outlook is cautiously optimistic with analyst consensus at Hold (65.71%) and price target of $23.40 below current price. Key opportunities include cost cuts and US production shift, while risks involve margin pressure and competitive threats. The stock faces headwinds from recent earnings misses but maintains dividend payments and institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →
